These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32072715)

  • 1. Sodium-glucose co-transporter 2 inhibitors and acute heart failure.
    Groenewegen A; Rutten FH
    Eur J Heart Fail; 2020 Apr; 22(4):723-725. PubMed ID: 32072715
    [No Abstract]   [Full Text] [Related]  

  • 2. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia.
    Khan MS; Butler J; Greene SJ
    Circ Heart Fail; 2020 Dec; 13(12):e008030. PubMed ID: 33161728
    [No Abstract]   [Full Text] [Related]  

  • 3. The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox.
    Carbone S; daSilva-deAbreu A; Lavie CJ
    Eur J Heart Fail; 2021 Oct; 23(10):1673-1676. PubMed ID: 34427026
    [No Abstract]   [Full Text] [Related]  

  • 4. Sodium-glucose co-transporter-2 inhibitors and cardiovascular outcome studies in people with type 2 diabetes: From efficacy to effectiveness.
    Khunti K; Kosiborod M
    Diabetes Obes Metab; 2018 Apr; 20(4):763-765. PubMed ID: 29077267
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on potassium handling in patients with acute heart failure.
    Beusekamp JC; Tromp J; Boorsma EM; Heerspink HJL; Damman K; Voors AA; van der Meer P
    Eur J Heart Fail; 2021 Jun; 23(6):1049-1052. PubMed ID: 33899306
    [No Abstract]   [Full Text] [Related]  

  • 6. Diving into the unknown: sodium-glucose cotransporter-2 inhibitors in heart failure without diabetes.
    Seferović PM; Seferović JP; Polovina MM
    Eur J Heart Fail; 2019 Jul; 21(7):874-876. PubMed ID: 31112012
    [No Abstract]   [Full Text] [Related]  

  • 7. SGLT2 inhibitors: expanding their Empire beyond diabetes.
    Muskiet MHA; Heerspink HJL; van Raalte DH
    Lancet Diabetes Endocrinol; 2021 Feb; 9(2):59-61. PubMed ID: 33357504
    [No Abstract]   [Full Text] [Related]  

  • 8. EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial.
    Liuzzo G; Patrono C
    Eur Heart J; 2020 Oct; 41(40):3881-3882. PubMed ID: 33026074
    [No Abstract]   [Full Text] [Related]  

  • 9. Emerging Topics in Heart Failure: Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) in HF.
    Bocchi EA; Biolo A; Moura LZ; Figueiredo Neto JA; Montenegro CEL; Albuquerque DC
    Arq Bras Cardiol; 2021 Feb; 116(2):355-358. PubMed ID: 33656089
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
    Crea F
    Eur Heart J; 2020 Sep; 41(36):3379-3383. PubMed ID: 33216881
    [No Abstract]   [Full Text] [Related]  

  • 11. Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness.
    Khan MS; Fonarow GC; Greene SJ
    Eur J Heart Fail; 2021 Jun; 23(6):1023-1025. PubMed ID: 33779013
    [No Abstract]   [Full Text] [Related]  

  • 12. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
    Katsiki N; Triposkiadis F
    Curr Vasc Pharmacol; 2019; 17(4):421-424. PubMed ID: 30173648
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism.
    Anker SD; Khan MS; Shahid I; Filippatos G; Coats AJS; Butler J
    Eur J Heart Fail; 2021 Aug; 23(8):1250-1255. PubMed ID: 34173305
    [No Abstract]   [Full Text] [Related]  

  • 14. Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.
    Chilton RJ
    Diabetes Obes Metab; 2021 May; 23(5):1215-1218. PubMed ID: 33464709
    [No Abstract]   [Full Text] [Related]  

  • 15. Empagliflozin Targeting the Real-World Heart Failure Population.
    Rocha BML; Gomes RV; Cunha GJL; Mendes G; Morais R; Campos L; Araújo I; Fonseca C
    J Card Fail; 2019 Mar; 25(3):218-219. PubMed ID: 30743044
    [No Abstract]   [Full Text] [Related]  

  • 16. Sodium-glucose co-transporter 2 inhibitors-the first successful treatment for heart failure with preserved ejection fraction?
    Petrie MC; Lee MMY; Docherty KF
    Eur J Heart Fail; 2021 Aug; 23(8):1256-1259. PubMed ID: 33502794
    [No Abstract]   [Full Text] [Related]  

  • 17. More Evidence for SGLT2 Inhibitors in Heart Failure.
    Jarcho JA
    N Engl J Med; 2020 Oct; 383(15):1481-1482. PubMed ID: 32865378
    [No Abstract]   [Full Text] [Related]  

  • 18. Sodium-glucose co-transporter 2 inhibitors in heart failure.
    Rosano GMC; Vitale C; Savarese G
    Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e9-e10. PubMed ID: 33576409
    [No Abstract]   [Full Text] [Related]  

  • 19. Comment on Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure.
    Cure E; Cumhur Cure M
    Am J Cardiol; 2020 May; 125(10):1602. PubMed ID: 32241553
    [No Abstract]   [Full Text] [Related]  

  • 20. Meta-Analysis Evaluating the Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Acute or Recently Decompensated Heart Failure.
    Patoulias D; Doumas M; Kassimis G; Fragakis N; Papadopoulos C
    Am J Cardiol; 2022 Jun; 172():171-172. PubMed ID: 35396145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.